- Business Wire•5 hours agoOpdivo (nivolumab) Demonstrated Efficacy and Improved Survival in Patients with Previously Treated Advanced Gastric Cancer in a Randomized Phase 3 Study
Bristol-Myers Squibb Company announced today the results of ONO-4538-12 demonstrating Opdivo significantly reduced the risk of death by 37% in patients with previously treated advanced gastric cancer refractory to or intolerant of standard therapy, a condition without current standard-of-care treatments.
- Zacks•5 hours ago
Bristol-Myers (BMY) is set to report fourth-quarter 2016 results on Jan 26. It reported a positive earnings surprise of 18.46% in the last quarter.
- TheStreet.com•2 days ago
The $101 billion market cap pharma could be put in play or targeted by an activist investor soon.
BMY : Summary for Bristol-Myers Squibb Company Co - Yahoo Finance
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Day's Range||55.34 - 56.31|
|52 Week Range||49.03 - 77.12|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||27.71|
|Dividend & Yield||1.56 (2.77%)|
|1y Target Est||N/A|